Related Experiment Video

Updated: May 8, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Development of an epidermal growth factor derivative with EGFR blocking activity

Clara Panosa1, Francesc Tebar, Montserrat Ferrer-Batallé

  • 1Biochemistry and Molecular Biology Unit. Department of Biology, University of Girona, Campus Montilivi, Girona, Catalunya, Spain.

Plos One
|August 13, 2013
PubMed

Insights

Researchers developed a truncated epidermal growth factor (EGFt) as a novel inhibitor for the epidermal growth factor receptor (EGFR). This EGFt molecule shows potential for cancer therapy by blocking EGFR and delivering toxins to tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The epidermal growth factor (EGF)/ErbB family are crucial targets in cancer therapy.
  • Current anti-ErbB therapies have limitations, necessitating novel inhibition strategies.
  • Identifying new molecules to inactivate ErbB receptors is a key goal in cancer research.

Purpose of the Study:

  • To develop a novel epidermal growth factor receptor (EGFR) inhibitor using a truncated form of human EGF (EGFt).
  • To investigate the inhibitory potential and therapeutic applications of EGFt in cancer treatment.

Main Methods:

  • Designed EGFt based on structural superimposition of EGF and Potato Carboxypeptidase Inhibitor (PCI).
  • Produced EGFt in E. coli, ensuring high yield and correct folding.
  • Assessed EGFt's affinity, dimerization, phosphorylation, internalization, and effects on cancer cell proliferation.

Main Results:

  • EGFt demonstrated specific, high-affinity binding to EGFR with minimal homodimerization and phosphorylation.
  • EGFt induced EGFR internalization and nuclear translocation without stimulating cell growth.
  • EGFt competed with native ligands, inhibiting cancer cell proliferation and demonstrating potential as a toxin delivery agent.

Conclusions:

  • EGFt is a promising novel EGFR inhibitor for cancer therapy.
  • The lack of growth-stimulatory activity makes EGFt suitable for targeted delivery of toxins to EGFR-overexpressing tumors.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular cells,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...